Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-236P** (RNA, U6 small nuclear 236, pseudogene) is a **pseudogene** derived from the U6 small nuclear RNA (snRNA) gene[4][5]. U6 snRNA is a core component of the spliceosome, catalyzing pre-mRNA splicing in the nucleus of eukaryotic cells[1]. However, **RNU6-236P is a non-functional copy** (“pseudogene”) and does not encode a functional snRNA or protein product[3][4][5]. Like other U6 pseudogenes, it may arise from retrotransposition events in the genome[3][5]. Pseudogenes, including those derived from U6 snRNA, generally **lack canonical biological functions** but may, in rare cases, be transcribed and could exert regulatory effects at the RNA level (e.g., acting as RNA decoys or influencing epigenetic regulation); however, there is **no evidence that RNU6-236P is involved in disease or has regulatory roles**[2][4]. It is not considered a therapeutic target, receptor, enzyme, or drug target, and there are **no drugs, biomarkers, or documented safety concerns** associated with this pseudogene[4]. In summary, **RNU6-236P is a genomic remnant of U6 snRNA with no known functional or therapeutic significance**.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 236, pseudogene (RNU6-236P).